Renew aging skin with Estrenue

A Targeted Dermal Estrogen Therapy using NOVEL Elongated Microparticle (EMP) platform

Estrenue is a treatment that delivers generic estradiol to the dermal layers of the skin utilizing a novel non-invasive micro-technology delivery system: Elongated Microparticles (EMP).

THE OPPORTUNITY

Estrenue is developing a reformulation for estradiol, which is expected to allow a faster and simplified path to FDA registration and commercialization.

Estrenue & University of South Australia have reached a very favorable option agreement to secure rights to a minimally invasive, elongated  technology.

Developed in partnership by Dr Stephen Birrell-Founder of Havah Therapeutics,  along with Professor Tarl Prow and Dr Miko Yamada, topical drug delivery experts from University of South Australia.

The team is beginning the initial Drug/Dose Ranging Studies to bind estradiol to microparticles for clinical use in a novel delivery platform in the treatment of aging skin soon.
.

THE TEAM

CHAIRMAN
.

Boris Bosnich

BEc, MBA

MANAGING DIRECTOR

Kathy Harrison

MSc, FIPTA, GAICD

CMO
CO-FOUNDER

Stephen Birrell

BMBS PhD FRACS

CTO
CO-FOUNDER

Dr Miko Yamada

PhD

CSO
CO-FOUNDER

Professor Tarl Prow

PhD

Corporate Advisor

Andrew Watson

Dip Ac, BAgEc, MAppFin

Business Development

Joe Schacter

.

THE SCIENCE

Current treatmentS to reverse estrogen loss

Estrogen has been demonstrated to have positive effects on skin health, reversing a number of the signs of aging in skin. However, elevated estrogen levels in the bloodstream can cause many side-effects including an increased risk for breast cancer, DVT and stroke.

THE HYPOTHESIS IS THAT THE APPLICATION OF ESTRENUE TO FACIAL SKIN, WILL IMPACT:

ESTRENUE TREATMENT OBJECTIVE ​

The estradiol is bound to the EMP and delivered directly to the dermal layer which is expected to restore aged skin without increasing blood estrogen levels.
Slow release and desired effect estimates repeat treatment every two months with unlimited usage.

Effects of aging on the skin

Source: Frost & Sullivan 2018

THE APPLICATOR

A novel transdermal elongated micro-particle (EMP) delivery system that introduces a therapeutic formulation (estradiol) into the dermal layer of the skin by gently painting it on with a proprietary microtextured applicator
Play Video

SCIENTIFIC ADVISORY BOARD ​

Stephen Birrell

Antony Condina

Dr. Michael Freeman

Dr. Mark Moore

Prof. Wayne Tilley

GET IN TOUCH

REACH OUT WITH ANY QUESTIONS

Boris Bosnich, BEc, MBA

Corporate Advisor

  • Experienced previous CEO leading to IPO of his private recruitment company
  • Currently Chairman/Director of SILK Laser Clinics, Ortho SA, Kid Sense Child development, Perks People Solution
  • Experienced advisor to SMEs in the US and Australia over diverse industries
  • Currently managing a range of venture development projects and capital raisings to accelerate growth strategy execution.

Kathy Harrison, MSc, FIPTA, GAICD

CEO

  • 25+ years of experience in the Australian Biotech sector, including 9 years in private Patent Attorney practice
  • Prior roles have spanned drug development and leadership including recently as CEO of ASX listed company Dimerix Ltd and is a current director of Disruptive Nutrition Pty Ltd
  • Kathy has extensive experience in IP strategy, commercial drug development strategy and achieving drug development milestones
  • Kathy’s unique combination of qualifications in science, IP law, and governance provide the depth of skill to lead Estrenue through its next stage of growth

Stephen Birrell, BMBS PhD FRACS

CMO

  • Internationally recognized expert in hormonal therapy in women
  • Breast Cancer Specialist with “bench-top to clinic” experience in drug development
  • Founded and was the Director for 20 years of one of Australia’s largest breast cancer clinics
  • Founder HAVAH Therapeutics-biotech holding over 25 patents
  • Founder Wellend Health-Breast and Hormone clinic for women
  • Adjunct academic Dame Roma Mitchell Laboratories Adelaide University

Dr Miko Yamada, PhD

CTO

Research Fellow, Medical Microtechnology Laboratory

Cell biologist, Molecular pathologist

  • Expert in running clinical research trials with 230 volunteers in 10 clinical research trials since 2014;
  • 25/33 publications with skin focus underpin expertise directly related to this project;
  • 50 volunteers in 5 drug delivery trials supporting the second stage of this project;
  •  

Professor Tarl Prow, PhD

CSO

Head Biomaterials Engineering and Nanomedicine Strand (Uni SA)

  • 189 publications that support his standing as a global, key opinion leader in skin and drug delivery;
  • 39 patent filings with 10 granted which illustrate his commitment to protecting valuable intellectual property;
  • >$2.81M in funding to develop EMP;
  • 17 EMP publications with >941 cites that support the feasibility of this project.

Andrew Watson, Dip Ac, BAgEc, MAppFin

Corporate Advisor

  • Professional skill set combining Corporate Advisory and direct operational management.
  • 15 year career in Investment Banking – Equity Capital Markets, capital raisings and M&A.
  • Operational management experience in development, capital management and transaction execution.
  • Advisory Board positions of privately owned high growth businesses, focus on Board governance, operations and compliance

Joe Schacter

usiness Development Director

  • Previous experience with Business Development and Operations at two technology startups
  • Prior to that, Joe was an Analyst on the licensing team at Torreya Partners, a boutique advisory firm in New York. He helped Torreya source Iota Biosciences, which Torreya founded and then was acquired by Astellas

Antony Condina, BPharm BSc

Scientific Advisory Board

  • Australian pharmacist who is the founder and CEO of Australian specialty pharmaceutical company GD Pharma
  • He has over 20 years of experience in the pharmacy and pharmaceutical industry with knowledge for customizing therapeutics by also running one of Australia’s largest compounding pharmacy facilities, the Green Dispensary Compounding Pharmacy
  • He has brought a few novel pharmaceutical products to market in Australia through the work in pain and addiction medicine. He has extensive knowledge of Pharmaceutical Formulation, R&D, GMP and Regulatory Affairs
  • His innovations and products have treated thousands of patients

Dr. Michael Freeman

Scientific Advisory Board

  • Lead dermatologist at The Skin Centre, specializing in Cosmetic and Laser Dermatology
  • Dr. Freeman is also the Director of Dermatology at the Gold Coast Hospital, a visiting Dermatologist at the Princess Alexandra Hospital in Brisbane, and is an Associate Professor of Dermatology at Bond University
  • Lead investigator in more than a dozen clinical trials, and educator for other dermatologists in the use of specialized lasers
  • While a fellow of the Australasian College of Dermatologists, he is also a member of the Skin and Cancer Foundation of Queensland and an international member of the American Academy of Dermatology

Dr. Mark Moore

Scientific Advisory Board

  • Head of Australian Craniofacial Unit (ACFU)
  • 30+ years of Plastic Surgery
  • Founding member of Asia-Pacific Craniofacial Association and Australia and New Zealand Society of Craniofacial Surgery and is a fully active member of the International Society of Craniofacial Surgery since 1999

Professor Wayne Tilley

SCIENTIFIC ADVISORY BOARD

  • Director of Dame Roma Mitchell Cancer Research Lab, Adelaide Medical School, the University of Adelaide
  • 40+ years of research across Australia, the US and UK, and has led to international acclaim as a world expert in the field of nuclear receptors and hormonal carcinogenesis
  • Internationally recognized for discoveries on steroid hormone receptor action, in particular androgen receptor (AR) structure and function and AR function in breast and prostate cancers